Article

Reduction of menstrual blood-loss by prostaglandin-synthetase inhibitors.

Nuffield Department of Obstetrics and Gynœcology, John Radcliffe Hospital, University of Oxford, Headington, Oxford, United Kingdom
The Lancet (Impact Factor: 39.06). 05/1976; 1(7963):774-6. DOI:10.1016/S0140-6736(76)91612-3
Source: PubMed

ABSTRACT Six patients with menorrhagia due to dysfunctional uterine bleeding and one patient with an intrauterine contraceptive device were treated with prostaglandin-synthetase inhibitors in an attempt to reduce their excessive menstrual blood-loss. Mefenamic acid (six patients) or flufenamic acid (one patient) taken during menstruation for 2-3 cycles reduced menstrual loss in each patient. These preliminary observations suggest a new treatment for a common gynaecological problem and could imply that prostaglandins are involved in the aetiology of excessive menstrual blood-loss in such patients.

0 0
 · 
0 Bookmarks
 · 
42 Views
  • [show abstract] [hide abstract]
    ABSTRACT: Hysterectomy is one of the most common surgical procedures performed in gynecological practice, and the most common indication for hysterectomy is menorrhagia or excessive menstrual bleeding. Approximately 10-15% of fertile women have menorrhagia, defined as a menstrual blood loss (MBL) of >80 mL. Since operative treatment in the form of a hysterectomy carries a not insignificant risk of morbidity and mortality, various forms of medical treatment have been advocated as initial treatment. Antifibrinolytic agents, e.g., tranexamic acid (40-50% reduction), prostaglandin synthetase inhibitors (20-25% reduction), oral contraceptives (40-50%) and the intrauterine release of progestin with the levonorgestrel-releasing intrauterine system (LNG-IUS; 86-97% reduction), have all been shown to reduce MBL and to be effective in the treatment of idiopathic menorrhagia. In comparative and noncomparative trials, the greatest reduction in MBL has been achieved with the LNG-IUS. Thus, this system has been proposed as an alternative to hysterectomy in women with menorrhagia. In a randomized controlled trial, the LNG-IUS was compared with hysterectomy. Only 42% of the women randomized to the LNG-IUS system subsequently underwent a hysterectomy during the 5-year observation period, and the total costs (direct and indirect) were 40% lower with the LNG-IUS than with hysterectomy. Despite the strong evidence that medical treatment and, in particular, the LNG-IUS are effective, many hysterectomies and endometrial ablations/resections are performed annually without first evaluating medical treatment.
    Contraception 06/2007; 75(6 Suppl):S152-4. · 3.09 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: IntroductionExcessive menstrual loss is a major problem. Effective medical treatments exist and may provide an alternative to surgery.
    Middle East Fertility Society Journal 01/2010; 15(3):163-167.
  • [show abstract] [hide abstract]
    ABSTRACT: A randomized, controlled, double-blind clinical trial was conducted to compare the effect of the prostaglandin synthetase inhibitor mefenamic acid (Ponstan) given during menstruation to that of a placebo in the treatment of menorrhagia. A statistically significant reduction in menstrual blood loss was recorded by 14 of 15 patients in the mefenamic acid group. The incidence of side effects was minimal. Placebo therapy was significantly more effective than no therapy. Further exploration of the use of mefenamic acid in patients with excessive menstrual loss is recommended.
    Australian and New Zealand Journal of Obstetrics and Gynaecology 06/2008; 18(2):135 - 138. · 1.30 Impact Factor

A B Anderson